Company news

Cantargia AB news in 2025

Cantargia AB's news releases, calls and decks from 2025, newest first.

View company

Cantargia Provides Update on Overall Survival Data from TRIFOUR

December 5, 2025

Cantargia Publishes Interim Report for January to September 2025

November 19, 2025

Cantargia Presents Nomination Committee Ahead of 2026 AGM

November 12, 2025

Invitation to the Presentation of Cantargia's Interim Report January-September 2025

November 5, 2025

Cantargia to Participate in Upcoming Conferences

October 23, 2025

Cantargia Appoints Dr. Wolfram Dempke As Chief Medical Officer

October 2, 2025

Cantargia Presents Data at an AACR Conference Strengthening IL1RAP as a Targetable Hallmark in PDAC

September 30, 2025

Cantargia Closes the Acquisition of CAN10 by Otsuka

September 11, 2025

Cantargia Granted Important US Patent for Nadunolimab

August 27, 2025

Cantargia Publishes Half-Year Report 2025

August 21, 2025

Cantargia Appoints Dr Hilde Steineger as Chief Executive Officer

August 18, 2025

Invitation to the Presentation of Cantargia's H1 2025 Report

August 12, 2025

Cantargia Announces Preliminary Topline Efficacy Results From the Phase 2 TRIFOUR Trial of Nadunolimab in Advanced Triple-Negative Breast Cancer (TNBC)

July 17, 2025

Cantargia Announces Publication of Clinical Data Showing Benefit of Nadunolimab Combination Therapy in Advanced Lung Cancer

July 16, 2025

Cantargia Announces the Acquisition of its CAN10 IL1RAP Immunology Program by Otsuka Pharmaceutical

July 15, 2025

Cantargia Signs SEK 50 Million Financing Facility Agreement, Extending Cash Runway Into 2026 and Providing Operating Flexibility to Drive Strategic Plans

June 17, 2025

Cantargia’s Nadunolimab Aantibody Awarded US FDA Fast Track Designation

June 11, 2025

Cantargia Publishes Promising Preclinical Results Highlighting CAN10's Potential to Inhibit Vascular Inflammation

May 19, 2025

Bulletin from the Annual General Meeting in Cantargia AB

May 15, 2025

Cantargia Publishes Interim Report for the First Quarter of 2025

May 13, 2025

Cantargia Announces Successful Phase 1 Results: PK/PD Data of Subcutaneously Administered CAN10 Confirms Every 4-Week Dosing Choice in Phase 2

May 12, 2025

Cantargia’s Announces Publication of Clinical Data Demonstrating Potential of Nadunolimab Plus Pembrolizumab in Solid Tumors

May 6, 2025

Invitation to the Presentation of Cantargia's Interim Report for Q1 2025

April 29, 2025

Cantargia Announces Selection of Treatment Resistant Atopic Dermatitis as Second Target Indication for CAN10

April 29, 2025

Cantargia Announces the Publication of Preclinical Data Highlighting Nadunolimab's Potential to Counteract Tumor-Driven Systemic Immunosuppression

April 28, 2025

Cantargia Presents Promising Preclinical Results on Anti-IL1RAP Antibody-Drug Conjugate (ADC) at a Major Cancer Conference

April 25, 2025

Cantargia Presents Association Between Nadunolimab and Reduction of Chemotherapy Induced Peripheral Neuropathy (CIPN) at AACR

April 25, 2025

Calls in 2025

Decks in 2025